TrialArthritis & rheumatology (Hoboken, N.J.)2018

Clinical Efficacy and Safety of Baminercept, a Lymphotoxin β Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial.

E William St Clair et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.